NCT00411229View on ClinicalTrials.gov

Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

1,035

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Stomach Neoplasms

Interventions

DRUG

Capecitabine

1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.

DRUG

Oxaliplatin

IV infusion, 130mg/m²

Trial Locations (3)

Unknown

Sanofi-Aventis, Beijing

Sanofi-Aventis, Seoul

Sanofi-Aventis, Taipei

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Sanofi

INDUSTRY